BioCryst to Report Second Quarter 2026 Financial Results on August 5
Rhea-AI Summary
BioCryst (Nasdaq:BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update, with live and replay access via the investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – BCRX
In the Jul 22 session, BCRX gained 0.96%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Earnings date | Neutral | -2.4% | Prior Q1 2026 earnings-date announcement scheduled the May 6 results release and webcast. |
| Feb 05 | Earnings date | Neutral | -2.8% | Prior Q4 2025 earnings-date announcement scheduled the February 26 results release and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The two prior earnings-date announcements both preceded negative 24-hour reactions, averaging -2.59%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com